Soleno Therapeutics weakness a buying opportunity, says Baird

Baird noted Soleno Therapeutics (SLNO) shares have traded, directionally, with Applied Therapeutics shares over the last couple of trading days, as they are both FDA regulatory plays on non-standard applications. However, since they are not directly comparable, Baird says they would use the weakness in Soleno Therapeutics as a buying opportunity and they maintain their Outperform rating and $72 price target on the shares.